Astellas Pharmaceuticals Group: Driven By Innovation
March 19, 2025 – Astellas Pharma Group (TSE: 4503) continues to demonstrate its innovative strength and market potential in the global pharmaceutical market.
As a pharmaceutical company specializing in the development and manufacture of innovative medicines, Astellas has demonstrated strong momentum in a number of therapeutic areas.
Product Development Progress
Astellas continues to invest in research and development in the areas of oncology, urology, immunology, nephrology and neuroscience to develop solutions to unmet medical needs.
Recently, Astellas has made significant progress in the field of gene therapy, achieving self-sufficiency in gene therapy programs from research to commercialization through the establishment of facilities in South San Francisco, California and Sanford.
North Carolina for in-house manufacturing and supply capabilities for adeno-associated virus (AAV) drugs, AAV products and plasmids.
Market Performance
Has performed well in the global market, especially in Greater China, where its performance has seen significant revenue growth.
In FY2021, Greater China’s performance grew by 11.8% year-on-year, demonstrating significant market potential.
In addition, Astellas’ product Vyloy (Zolbetuximab) was approved by the U.S.
FDA for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal-joint (GEJ) adenocarcinoma, which is the first FDA-approved CLDN18.2 targeted therapy.
Social Responsibility Activities
Astellas Peficitinib is active in corporate social responsibility, contributing to the sustainable development of society by providing healthcare solutions to meet unmet medical needs, and has been named to the FTSE4Good Index Series and included in the Japan Government Pension Investment Fund (JGPIF).
Astellas is included in the FTSE4Good Index Series and is included in all ESG investment indices used by Japan’s Government Pension Investment Fund (GPIF), demonstrating its excellence in environmental, social and corporate governance.
About Astellas Pharma Inc
Astellas Pharma Inc. is a leading global pharmaceutical company dedicated to providing patients with valuable therapeutic solutions through innovative science.
With a focus on research and development in the areas of oncology, urology, immunology, and rare diseases, the company aims to improve the quality of life for patients around the world.
Astellas is headquartered in Tokyo, Japan, and has operations in more than 70 countries around the world.
We welcome you to reach out to us to buy Peficitinib. DengYueMedicine is here to provide detailed medicine information, pricing, and support to ensure a smooth and reliable buying experience.
Feel free to contact us anytime to discuss your needs or ask any questions about the medicine.
Information from DengYueMed, China Drug Import and Export Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
